Active Pharmacovigilance of Anti-cancer Medicines

Status Recruiting

Clinical Trial Summary

Pharmacovigilance (PV), defined by the World Health Organization (WHO) as the "science and activities related to the detection, evaluation, understanding and prevention of adverse effects or any other drug-related problem", aims to improve patient safety and quality of life. There are several objectives of PV, starting with the collection and management of safety data, to promote the safe and effective use of medicines. PV also aims to provide information on drug safety to health professionals and patients, and it contributes to updating drug labels. Finally, it is active in risk management, risk minimization and the prevention of adverse effects and other drug-related problems. As defined by WHO, an adverse event (AE) is "any untoward medical occurrence that may be present during treatment with a medicine, but which does not necessarily have a causal relationship with this treatment". When there is a causal relationship with the treatment, an AE is classified as an adverse drug reaction (ADR). The collection and reporting of AEs is a process that starts from the drug development phase and proceeds continuously throughout the life cycle of the drug, and it aims to assess the benefits-to-toxicity ratios (in other words, the safety and efficacy) of all medicines. Reports of ADRs must accurately describe the case and be meaningful to health professionals worldwide. The aim of this project is to evaluate the impact of an active prescription surveillance of anti-cancer drugs carried out by the clinical pharmacist in pediatrics and young adults.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05825794
Study type	Observational
Source	IRCCS Burlo Garofolo
Contact	Marta Paulina Trojniak, PharmD
Phone	+390403785111
Email	martapaulina.trojniak@burlo.trieste.it
Status	Recruiting
Phase
Start date	October 28, 2021
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01439152` - Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.	Phase 1
Recruiting	`NCT05615246` - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Active, not recruiting	`NCT06015009` - Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers	N/A
Active, not recruiting	`NCT03298100` - Risk Scoring Model for Endometrial Cancer
Recruiting	`NCT05055609` - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	Phase 1
Not yet recruiting	`NCT04324320` - Psychological Distress in Outpatient Oncological Rehabilitation
Completed	`NCT00588289` - Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA	N/A
Recruiting	`NCT06222801` - The 1st Tumor CytokinoTherapy Database (TCTD-1)
Recruiting	`NCT03831633` - Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients	Phase 4
Completed	`NCT04914702` - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting	`NCT05198570` - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting	`NCT05712174` - A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer	Phase 2
Recruiting	`NCT03832062` - Value of Analysing Under-utilised Leftover Tissue (VauLT)
Completed	`NCT03988777` - Magnetic Seed Localisation for Nonpalpable Breast Lesions
Recruiting	`NCT06031233` - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	Phase 4
Enrolling by invitation	`NCT04019119` - Digital Intervention for the Modification of Lifestyles (iGame)	N/A
Not yet recruiting	`NCT05926362` - Capillary-Venous Paired Data Collection
Recruiting	`NCT05686213` - ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial	Phase 2
Recruiting	`NCT05510856` - Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients	Phase 4
Completed	`NCT04180306` - PEWS Implementation in an LMIC Setting	N/A